COVID-19: an update on diagnostic and therapeutic approaches

Mahalaxmi Iyer1, Kaavya Jayaramayya1, Mohana Devi Subramaniam2

  • 1Department of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore 641-043, India.

BMB Reports
|April 28, 2020
PubMed

Insights

The COVID-19 pandemic necessitates rapid development of diagnostics and therapeutics. This review covers updated diagnostic methods and treatments, including repurposed drugs like hydroxychloroquine and convalescent plasma, for controlling SARS-CoV-2.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, has prompted urgent global efforts to develop effective diagnostics and treatments.
  • Current strategies involve limiting viral replication and managing immune-mediated tissue damage.

Discussion:

  • This review examines advancements in specimen collection, efficient diagnostic tools, and therapeutic interventions for COVID-19.
  • It highlights the repurposing of existing drugs, such as chloroquine/hydroxychloroquine, and the use of convalescent plasma (CP) as potential treatments.

Key Insights:

  • Repurposed therapeutics, including hydroxychloroquine and convalescent plasma, have demonstrated clinical effectiveness against COVID-19.
  • Rapid development of diagnostic algorithms is crucial for identifying and containing the virus.
  • A multifaceted approach combining diagnostics, therapeutics, and control measures is essential.

Outlook:

  • Further research is needed to fully understand the impact of diagnostics and therapeutics on COVID-19 outcomes.
  • Continued investigation is vital for the development of novel vaccines and drugs to combat the virus.
  • Global collaboration is key to addressing the ongoing challenges posed by the pandemic.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
665
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
204
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
119
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
166
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
643
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
473